T-Cell Lymphoma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017

  • ID: 4449818
  • Report
  • Region: Global
  • 359 pages
  • VPA Research
1 of 3
Lymphoma is a cancer type where uncontrollable growth of lymphocytes (WBCs) initiating from lymph glands or lymphatic tissue or other parts of the lymphatic system, including bone marrow, tonsils, testicles, spleen and lymph nodes.

This excess growth of lymphocytes often accumulates in lymph nodes. Though this accumulation can occur in any body part, commonly affected parts are armpits, neck and groin and rarely in lungs or bones.

The non- inheritable and non- contageous disease is one of the common types of cancer but can be treated with patients’ life expectancy remaining quite large post- treatment.

Genomic alterations in lymphocytes cause damage to the lifecycle of these cells, boosting the cell division rate or affecting the death period. However, causes for such gene changes are yet to be determined.

Phases:
Phases of Lymphoma cancer
  • Single group of lymph nodes (above or below diaphragm)
  • Multiple group of lymph nodes are affected(above or below diaphragm)
  • Expands to both sides of diaphragm
  • Expands to bone marrow or other body parts
Types of Lymphoma Cancer

Though two types of Lymphoma are defined, it is often difficult to determine the exact sub- type of Lymphoma.

* Hodgkin Lymphoma
In Hodgkin Lymphoma, the cancer cells called Reed- Sternberg (RS) cells, have a characteristic appearance under microscope.
Further subtypes-

Nodular Sclerosis: Lymph nodes contain Reed- Sternberg cells mixed with normal white blood cells

Mixed Cellularity: Lymph nodes contain several Reed- Sternberg cells in addition to several other cell types

Lymphocyte- rich: Lymph nodes contain several normal- appearing lymphocytes and classic Reed- Sternberg cells

Lymphocyte- depleted: Lymph nodes contain large volume of Reed- Sternberg cells and few normal lymphocytes

Nodular lymphocyte- predominant Hodgkin lymphoma: Lymph nodes contain several abnormal B cells and Reed- Sternberg cells are rarely observed

* Non- Hodgkin Lymphoma
Unlike Hodgkin Lymphoma, the cancer cells called Reed- Sternberg cells are absent in this subtype of Lymphoma

High grade NHL

* B- cell NHL Lymphoma
Diffuse large B- cell (DLBCL): Abnormal growth of large B- Cells in different body parts

Intravascular B- Cell: Occurs due to explosion of lymphocytes within tiny vessels with no involvement of the organ parenchyma

Primary mediastinal large B- cell: Large neoplastic cells with B- cell derivation are observed

Burkitt: Most aggressive form, classified as endemic (African) type, sporadic type and HIV related

Primary central nervous system: DLBCL sub- type affecting the brain and or spinal cord

* T- cell NHL Lymphoma
Peripheral T- cell (PTCL NOS): Abnormal growth of T- cells which are not specified under any category

Anaplastic large cell: It can occur in the skin or in other organs throughout the body

Angioimmunoblastic T- cell: the body’s immune system does not recognize, and consequently destroys, its own cells and tissues

Enteropathy- associated: occurs in the intestines and is mostly associated with celiac disease

Nasal- type NK/T- cell: Natural killer cells often affecting the nasal area, trachea, gastrointestinal tract, or skin

Hepatosplenic T- cell: Abnormal growth of T- cells in liver or spleen

Lymphoblastic: The T- cells outgrow in number when a bone marrow cell develops alterations in its gene code

Low Grade NHL
Follicular: B- cells are affected; Enlargement of the lymph nodes in the neck, underarm, stomach, groin

Small lymphocytic: B- lymphocytes, with enlarged nodes affecting neck, armpit or groin

Lympho- plasmacytic: Enlarged cells make varying volumes of immunoglobin M protein in the blood, making it thick (condition referred to as Waldenstrom macroglobulinemi)

MALT Lymphoma (Gastric and Non- gastric): mucosa- associated lymphoid tissue (MALT) starts outside lymph nodes, usually in lymphatic tissue in the mucous membranes or tissues lining organs

Splenic marginal zone: The NHL sub- type affects spleen, bone marrow and blood

Nodal marginal zone: Mostly occurs in lymph nodes and rarely in spleen or bone marrow
T- Cell Lymphoma clinical trials report provides comprehensive analysis and trends in global T- Cell Lymphoma disease clinical trials. The research work analyzes the evolution of T- Cell Lymphoma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for T- Cell Lymphoma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to T- Cell Lymphoma clinical trials.

Major drugs under development in T- Cell Lymphoma are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.

Scope of the Report
  • Number of T- Cell Lymphoma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of T- Cell Lymphoma
  • Both observational and interventional trials analyzed
  • Success rates of trials are analyzed
  • Trends in enrollment over the past ten years identified
  • Leading sponsors of T- Cell Lymphoma clinical trials worldwide are listed
Reasons to Buy
  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
High grade NHL
Low Grade NHL
2.1 Report Guide
2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Initiated in 2017
2.2.2 Average Enrolment by Country, 2010- 2017
2.2.3 Prominent Companies in Global T-Cell Lymphoma Trials, 2010- 2017

3 T-Cell Lymphoma Drugs in Ongoing and Completed Trials
3.1 Prominent Drugs in Development and Approved Stages for T-Cell Lymphoma
3.2 T-Cell Lymphoma Product Snapshots
3.2.1 T-Cell Lymphoma Drug Profiles

4 Global T-Cell Lymphoma Clinical Trial Research Trends
4.1 Clinical Trials by Top 10 Countries, 2010- 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing/Planned Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010- 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010- 2017
4.4 Subjects Recruited by Region, 2010- 2017
4.5 Clinical Trials by Year, 2010- 2017
4.6 Subjects Recruited by Year, 2010- 2017
4.7 Clinical Trials by Development Phase, 2010- 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010- 2017
4.9 Clinical Trials by Status, 2010- 2017
4.10 Subjects Recruited by Trial Status, 2010- 2017
4.11 Clinical Trials by Sponsor Type, 2010- 2017
4.12 Subjects Recruited by Sponsor Type, 2010- 2017
4.13 Clinical Trials by Economy Type, 2010- 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010- 2017

5 Europe T-Cell Lymphoma Clinical Trial Research Trends
5.1 Clinical Trials by Top Countries in Europe, 2010- 2017
5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010- 2017
5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010- 2017
5.4 Europe, Clinical Trials by Development Phase, 2010- 2017
5.5 Europe, Clinical Trials by Trial Status, 2010- 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010- 2017

6 Western Pacific T-Cell Lymphoma Clinical Trial Research Trends
6.1 Clinical Trials by Top Countries in Western Pacific, 2010- 2017
6.1.1 Western Pacific, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in Western Pacific, 2010- 2017
6.2.1 Western Pacific, Total Enrolment by Country
6.3 Western Pacific, Clinical Trials by Year, 2010- 2017
6.4 Western Pacific, Clinical Trials by Development Phase, 2010- 2017
6.5 Western Pacific, Clinical Trials by Trial Status, 2010- 2017
6.6 Western Pacific, Clinical Trials by Sponsor Type, 2010- 2017

7 Eastern Mediterranean T-Cell Lymphoma Clinical Trial Research Trends

8 South East Asia T-Cell Lymphoma Clinical Trial Research Trends
8.1 Clinical Trials by Top Countries in South East Asia, 2010- 2017
8.1.1 South East Asia, Clinical Trials by Country
8.2 Subjects Recruited by Top Countries in South East Asia, 2010- 2017
8.2.1 South East Asia, Total Enrolment by Country
8.3 South East Asia, Clinical Trials by Year, 2010- 2017
8.4 South East Asia, Clinical Trials by Development Phase, 2010- 2017
8.5 South East Asia, Clinical Trials by Trial Status, 2010- 2017
8.6 South East Asia, Clinical Trials by Sponsor Type, 2010- 2017

9 North America T-Cell Lymphoma Clinical Trial Research Trends
9.1 Clinical Trials by Top Countries in North America, 2010- 2017
9.1.1 North America, Clinical Trials by Country
9.2 Subjects Recruited by Top Countries in North America, 2010- 2017
9.2.1 North America, Total Enrolment by Country
9.3 North America, Clinical Trials by Year, 2010- 2017
9.4 North America, Clinical Trials by Development Phase, 2010- 2017
9.5 North America, Clinical Trials by Trial Status, 2010- 2017
9.6 North America, Clinical Trials by Sponsor Type, 2010- 2017

10 South and Central America T-Cell Lymphoma Clinical Trial Research Trends
10.1 Clinical Trials by Top Countries in South and Central America, 2010- 2017
10.1.1 South and Central America, Clinical Trials by Country
10.2 Subjects Recruited by Top Countries in South and Central America, 2010- 2017
10.2.1 South and Central America, Total Enrolment by Country
10.3 South and Central America, Clinical Trials by Year, 2010- 2017
10.4 South and Central America, Clinical Trials by Development Phase, 2010- 2017
10.5 South and Central America, Clinical Trials by Trial Status, 2010- 2017
10.6 South and Central America, Clinical Trials by Sponsor Type, 2010- 2017

11 Recent Clinical Trials- Snapshots
11.1 T-Cell Lymphoma Trial Snapshots- 2017
11.2 T-Cell Lymphoma Trial Snapshots- 2016
11.3 T-Cell Lymphoma Trial Snapshots- 2015
11.4 T-Cell Lymphoma Trial Snapshots- 2014
11.5 T-Cell Lymphoma Trial Snapshots- 2013
11.6 T-Cell Lymphoma Trial Snapshots- 2012
11.7 T-Cell Lymphoma Trial Snapshots- 2011
11.8 T-Cell Lymphoma Trial Snapshots- 2010

12 Appendix
12.1 About the Author
12.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: T-Cell Lymphoma- Average Enrolment by Country, 2010- 2017
Figure 2: T-Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 3: T-Cell Lymphoma- Country wise Recruiting Sites, 2010- 2017
Figure 4: T-Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 5: Global T-Cell Lymphoma Clinical Trials Participation Share by Region, 2010- 2017
Figure 6: Global T-Cell Lymphoma Subjects Recruited by Region, 2010- 2017
Figure 7: Global T-Cell Lymphoma Clinical Trials by Year, 2010- 2017
Figure 8: Global T-Cell Lymphoma Subjects Recruited by Year, 2010- 2017
Figure 9: Global T-Cell Lymphoma Trials by Phase, 2010- 2017
Figure 10: Global T-Cell Lymphoma- Subjects Recruited by Phase, 2010- 2017
Figure 11: Global T-Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 12: Global T-Cell Lymphoma- Subjects Recruited by Trial Status, 2010- 2017
Figure 13: Global T-Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 14: Global T-Cell Lymphoma- Subjects Recruited by Trial Status, 2010- 2017
Figure 15: Global T-Cell Lymphoma- Clinical Trials by Type of Economy, 2010- 2017
Figure 16: Europe T-Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 17: Europe T-Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 18: Europe T-Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 19: Europe T-Cell Lymphoma Trials by Phase, 2010- 2017
Figure 20: Europe T-Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 21: Europe T-Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 22: Western Pacific T-Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 23: Western Pacific T-Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 24: Western Pacific T-Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 25: Western Pacific T-Cell Lymphoma Trials by Phase, 2010- 2017
Figure 26: Western Pacific T-Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 27: Western Pacific T-Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 28: South East Asia T-Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 29: South East Asia T-Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 30: South East Asia T-Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 31: South East Asia T-Cell Lymphoma Trials by Phase, 2010- 2017
Figure 32: South East Asia T-Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 33: South East Asia T-Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 34: North America T-Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 35: North America T-Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 36: North America T-Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 37: North America T-Cell Lymphoma Trials by Phase, 2010- 2017
Figure 38: North America T-Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 39: North America T-Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 40: South and Central America T-Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 41: South and Central America T-Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 42: South and Central America T-Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 43: South and Central America T-Cell Lymphoma Trials by Phase, 2010- 2017
Figure 44: South and Central America T-Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 45: South and Central America T-Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017

1.2 List of Tables
Table 1: T-Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (1)
Table 2: T-Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (2)
Table 3: T-Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (3)
Table 4: T-Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (4)
Table 5: T-Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (5)
Table 6: T-Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (6)
Table 7: T-Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (7)
Table 8: T-Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (8)
Table 9: T-Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (9)
Table 10: T-Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (10)
Table 11: T-Cell Lymphoma- Region wise Clinical Trials, 2010- 2017
Table 12: T-Cell Lymphoma- Region wise Subjects Recruited, 2010- 2017
Table 13: Global T-Cell Lymphoma- Clinical Trials and Subjects by Trial Type, 2010- 2017
Table 14: T-Cell Lymphoma Trial Snapshots- 2017
Table 15: T-Cell Lymphoma Trial Snapshots- 2017
Table 16: T-Cell Lymphoma Trial Snapshots- 2017
Table 17: T-Cell Lymphoma Trial Snapshots- 2017
Table 18: T-Cell Lymphoma Trial Snapshots- 2017
Table 19: T-Cell Lymphoma Trial Snapshots- 2017
Table 20: T-Cell Lymphoma Trial Snapshots- 2017
Table 21: T-Cell Lymphoma Trial Snapshots- 2017
Table 22: T-Cell Lymphoma Trial Snapshots- 2017
Table 23: T-Cell Lymphoma Trial Snapshots- 2017
Table 24: T-Cell Lymphoma Trial Snapshots- 2017
Table 25: T-Cell Lymphoma Trial Snapshots- 2017
Table 26: T-Cell Lymphoma Trial Snapshots- 2017
Table 27: T-Cell Lymphoma Trial Snapshots- 2017
Table 28: T-Cell Lymphoma Trial Snapshots- 2017
Table 29: T-Cell Lymphoma Trial Snapshots- 2017
Table 30: T-Cell Lymphoma Trial Snapshots- 2017
Table 31: T-Cell Lymphoma Trial Snapshots- 2017
Table 32: T-Cell Lymphoma Trial Snapshots- 2017
Table 33: T-Cell Lymphoma Trial Snapshots- 2017
Table 34: T-Cell Lymphoma Trial Snapshots- 2017
Table 35: T-Cell Lymphoma Trial Snapshots- 2017
Table 36: T-Cell Lymphoma Trial Snapshots- 2017
Table 37: T-Cell Lymphoma Trial Snapshots- 2017
Table 38: T-Cell Lymphoma Trial Snapshots- 2017
Table 39: T-Cell Lymphoma Trial Snapshots- 2017
Table 40: T-Cell Lymphoma Trial Snapshots- 2017
Table 41: T-Cell Lymphoma Trial Snapshots- 2017
Table 42: T-Cell Lymphoma Trial Snapshots- 2017
Table 43: T-Cell Lymphoma Trial Snapshots- 2017
Table 44: T-Cell Lymphoma Trial Snapshots- 2017
Table 45: T-Cell Lymphoma Trial Snapshots- 2017
Table 46: T-Cell Lymphoma Trial Snapshots- 2017
Table 47: T-Cell Lymphoma Trial Snapshots- 2017
Table 48: T-Cell Lymphoma Trial Snapshots- 2017
Table 49: T-Cell Lymphoma Trial Snapshots- 2017
Table 50: T-Cell Lymphoma Trial Snapshots- 2017
Table 51: T-Cell Lymphoma Trial Snapshots- 2017
Table 52: T-Cell Lymphoma Trial Snapshots- 2017
Table 53: T-Cell Lymphoma Trial Snapshots- 2017
Table 54: T-Cell Lymphoma Trial Snapshots- 2017
Table 55: T-Cell Lymphoma Trial Snapshots- 2017
Table 56: T-Cell Lymphoma Trial Snapshots- 2017
Table 57: T-Cell Lymphoma Trial Snapshots- 2017
Table 58: T-Cell Lymphoma Trial Snapshots- 2017
Table 59: T-Cell Lymphoma Trial Snapshots- 2017
Table 60: T-Cell Lymphoma Trial Snapshots- 2017
Table 61: T-Cell Lymphoma Trial Snapshots- 2017
Table 62: T-Cell Lymphoma Trial Snapshots- 2017
Table 63: T-Cell Lymphoma Trial Snapshots- 2017
Table 64: T-Cell Lymphoma Trial Snapshots- 2017
Table 65: T-Cell Lymphoma Trial Snapshots- 2017
Table 66: T-Cell Lymphoma Trial Snapshots- 2017
Table 67: T-Cell Lymphoma Trial Snapshots- 2017
Table 68: T-Cell Lymphoma Trial Snapshots- 2017
Table 69: T-Cell Lymphoma Trial Snapshots- 2016
Table 70: T-Cell Lymphoma Trial Snapshots- 2016
Table 71: T-Cell Lymphoma Trial Snapshots- 2016
Table 72: T-Cell Lymphoma Trial Snapshots- 2016
Table 73: T-Cell Lymphoma Trial Snapshots- 2016
Table 74: T-Cell Lymphoma Trial Snapshots- 2016
Table 75: T-Cell Lymphoma Trial Snapshots- 2016
Table 76: T-Cell Lymphoma Trial Snapshots- 2016
Table 77: T-Cell Lymphoma Trial Snapshots- 2016
Table 78: T-Cell Lymphoma Trial Snapshots- 2016
Table 79: T-Cell Lymphoma Trial Snapshots- 2016
Table 80: T-Cell Lymphoma Trial Snapshots- 2016
Table 81: T-Cell Lymphoma Trial Snapshots- 2016
Table 82: T-Cell Lymphoma Trial Snapshots- 2016
Table 83: T-Cell Lymphoma Trial Snapshots- 2016
Table 84: T-Cell Lymphoma Trial Snapshots- 2016
Table 85: T-Cell Lymphoma Trial Snapshots- 2016
Table 86: T-Cell Lymphoma Trial Snapshots- 2016
Table 87: T-Cell Lymphoma Trial Snapshots- 2016
Table 88: T-Cell Lymphoma Trial Snapshots- 2016
Table 89: T-Cell Lymphoma Trial Snapshots- 2016
Table 90: T-Cell Lymphoma Trial Snapshots- 2016
Table 91: T-Cell Lymphoma Trial Snapshots- 2016
Table 92: T-Cell Lymphoma Trial Snapshots- 2016
Table 93: T-Cell Lymphoma Trial Snapshots- 2016
Table 94: T-Cell Lymphoma Trial Snapshots- 2016
Table 95: T-Cell Lymphoma Trial Snapshots- 2016
Table 96: T-Cell Lymphoma Trial Snapshots- 2016
Table 97: T-Cell Lymphoma Trial Snapshots- 2016
Table 98: T-Cell Lymphoma Trial Snapshots- 2016
Table 99: T-Cell Lymphoma Trial Snapshots- 2016
Table 100: T-Cell Lymphoma Trial Snapshots- 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll